SCHEMBL2704342

SCHEMBL2704342

COc1ccc(C(F)(F)F)cc1N(C(N)=O)c1ccc(Oc2ccnc(C(N)=O)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 5/20 0.51
SCN9A Q15858 9/20 0.43
KDR P35968 2/20 0.41
PLK4 O00444 1/20 0.41
AURKA O14965 1/20 0.41
MAPK13 O15264 1/20 0.41
JAK2 O60674 1/20 0.41
MAP4K4 O95819 1/20 0.41
ABL1 P00519 1/20 0.41
LCK P06239 1/20 0.41
FYN P06241 1/20 0.41
LYN P07948 1/20 0.41
RET P07949 1/20 0.41
ROS1 P08922 1/20 0.41
SRC P12931 1/20 0.41
RPS6KB1 P23443 1/20 0.41
EPHA2 P29317 1/20 0.41
TYK2 P29597 1/20 0.41
AXL P30530 1/20 0.41
FRK P42685 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2705545 0.91 RAF1 (0.62) RAF1KDRPLK4AURKAMAPK13
SCHEMBL2704896 0.91 RAF1 (0.46) RAF1SCN9AKDRPLK4AURKA
SCHEMBL6249040 0.88 RAF1 (0.43) RAF1SCN9AKDRMAPK14TNNI3K
SCHEMBL2702766 0.82 RAF1 (0.56) RAF1KDRPLK4AURKAMAPK13
SCHEMBL7964989 0.81 RAF1 (0.53) RAF1KDRPLK4AURKAMAPK13
SCHEMBL27576010 0.80 RAF1 (0.47) RAF1SCN9AKDRPLK4AURKA
SCHEMBL13388168 0.79 RAF1 (0.43) RAF1MAPK13
SCHEMBL6364181 0.78 POLQ (0.41) SCN10A
SCHEMBL13388545 0.78 MAPT (0.43) SCN10A
SCHEMBL13388575 0.78 RAF1 (0.61) RAF1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2298311-B1 w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors BAYER HEALTHCARE LLC (US) 2012-05-09 EP claimed
US-20010027202-A1 Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors BAYER HEALTHCARE LLC 2001-10-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027202-A1 Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors BRAF, NRAS, ARAF RAF1 4/4885SCN9A 4752/4885KDR 487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.